The FDA has retracted its request to study the risks associated with kratom and psychedelics, a move that’s being celebrated by advocates who had criticized the initial proposal, viewing it as a continuation of what they perceive as FDA bias against these substances.

Kratom products.
On August 2, the FDA announced plans in the Federal Register to open a 60-day public comment period on the proposed study, pending clearance from the White House Office of Management and Budget (OMB). However, the agency unexpectedly withdrew the notice on Monday.
The American Kratom Association (AKA) applauded the announcement of the FDA’s decision to withdraw its proposal.
Continue reading